Vaxcyte

PCVX

Market cap $4.01B

Overview Fund Activity

30.89 USD

-0.34

1.09%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

30.89

0.00

0%

1 day

-1.09%

5 days

-3.86%

1 month

-3.74%

3 months

-8.17%

6 months

-58.94%

Year to date

-62.92%

1 year

-73.54%

5 years

-37.49%

10 years

18.13%

About: Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Employees: 414

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

124% more call options, than puts

Call options by funds: $12M | Put options by funds: $5.37M

72% more repeat investments, than reductions

Existing positions increased: 129 | Existing positions reduced: 75

14% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 8 (+1) [Q2]

1.74% more ownership

Funds ownership: 112.59% [Q1] → 114.33% (+1.74%) [Q2]

6% less funds holding

Funds holding: 310 [Q1] → 291 (-19) [Q2]

18% less capital invested

Capital invested by funds: $5.85B [Q1] → $4.8B (-$1.05B) [Q2]

22% less first-time investments, than exits

New positions opened: 58 | Existing positions closed: 74

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$38

23% upside

Avg. target

$38

23% upside

High target

$38

23% upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Goldman Sachs

Asad Haider

$38

Neutral

Initiated

12 Sep 2025

See Analyst Rankings

Financial journalist opinion

Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Vaxcyte, Inc. (NASDAQ:PCVX ) Cantor Global Healthcare Conference 2025 September 3, 2025 2:45 PM EDT Company Participants Grant Pickering - Co-Founder, CEO & Director Andrew Guggenhime - President & CFO James Wassil - Executive VP & COO Conference Call Participants Carter Gould - Cantor Fitzgerald & Co., Research Division Presentation Carter Gould Research Analyst Okay. Good afternoon.

Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD)

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

The Motley Fool

Vaxcyte (PCVX) Q2 Loss Widens 11%

Vaxcyte (PCVX) Q2 Loss Widens 11%

Vaxcyte (PCVX) Q2 Loss Widens 11%

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Following Interactions with FDA on VAX-31 Adult Program, Including End-of-Phase 2 Meeting, Company Finalizing Phase 3 Clinical Program to Validate VAX-31 as Potential New Standard-of-Care Adult PCV ; Pivotal, Non-Inferiority Study Expected to be Initiated in Fourth Quarter of 2025 with Topline Data in 2026 FDA Provided Input on VAX-31 Adult CMC Licensure Requirements Facilitating Progression to Phase 3; Company Plans to Seek Ongoing Input as Program Advances Company Expects Multiple VAX-31 Adult Phase 3 Program Data Readouts in 2026 and 2027 to Support Biologics License Application Submission For VAX-31 Pediatric Program, Company Modifies Ongoing Infant Phase 2 Dose-Finding Study to Add a VAX-31 Optimized Dose Arm (4.4mcg/3.3mcg) and Discontinues Enrollment of Low Dose Arm; Enrollment in Modified Study Expected to Proceed by End of Third Quarter of 2025 with Topline Data from Both Primary Immunization Series and Booster Dose by End of First Half of 2027 Company Remains Focused on Disciplined Capital Allocation; Streamlining Early-Stage Pipeline to Prioritize Resources for PCV Programs and Further Extend Cash Runway Approximately $2.8 Billion in Cash, Cash Equivalents and Investments as of June 30, 2025 SAN CARLOS, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update, highlighting key clinical and regulatory progress for VAX-31, a potential best-in-class pneumococcal conjugate vaccine (PCV).

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later --

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors.

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Zacks Investment Research

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

Zacks Investment Research

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

CNBC Television

Vaccine stocks fall following FDA resignation

Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.

Vaccine stocks fall following FDA resignation

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

See News Rankings

Charts implemented using Lightweight Charts™